clinical trial · NCT00777985
Preventive Effects of Bosentan on the Systemic Cardiovascular Consequence of Sleep Apnea
University Hospital, Grenoble·phase2·completed·n = 19
Obstructive Sleep ApneaHypertensionbosentannasal continuous positive airway pressure (CPAP)
brief summary
The study will compared the effects of bosentan, an endothelin receptor antagonist, and nasal continuous positive airway pressure (nCPAP), obstructive sleep apnea current reference treatment, on diastolic blood pressure in untreated mildly hypertensive sleep apnea patients. The hypothesis is that blocking endothelin receptors with a drug will have the same systemic blood pressure lowering effect than nCPAP in sleep apnea patients.
started
Dec 1, 2007
primary completion
Jan 1, 2012
completion
Jan 1, 2012
last updated
Dec 22, 2025
official title
Cardiovascular Consequences of Obstructive Sleep Apnea (OSA): Role of Endothelin and Preventive Effects of Bosentan
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol